INTRODUCTION {#s1}
============

In advanced cancers, hypercalcemia is a metabolic disorder that occurs in 10% to 30% of patients during the course of their disease^[@B1]^ and leads to a 50% death rate within 30 days of diagnosis.^[@B2]^ Since the 1990s, bisphosphonates (BPs) have been used in patients with bone metastasis to prevent or delay skeletal-related events; provide better symptom control^[@B3]^; and, thus, contribute to reduced hypercalcemia incidence.^[@B4]^ BPs are effective in controlling hypercalcemia, with most patients achieving calcium control by day 10 (approximately 90% of those treated with zoledronic acid and approximately 70% with pamidronate).^[@B5]^ However, the median time to relapse is short (range, 30-40 days with zoledronic acid and 17 days with pamidronate).^[@B5]^ Retreatment of relapse and of primary refractory patients with a higher dose of zoledronic acid (8 mg) has proven less effective (response rate, 52%; median time to relapse, 8 days).^[@B5]^ Serum calcium normalization does not improve prognosis according to previous series, which prompts the need for antitumor therapy.^[@B6]^ Besides the importance of BPs in the palliative care setting, some performance status (PS) amelioration is important until active cancer treatment can be started.

Given that few studies have evaluated the impact of cancer treatment in the outcome of patients with hypercalcemia,^[@B2],[@B7]^ whether the proper selection of patients and the use of newer therapies improve prognosis is not clear. We aimed to evaluate survival outcomes and prognostic factors in a contemporary series of patients with malignancy-related hypercalcemia (MRH).

PATIENTS AND METHODS {#s2}
====================

Three hundred six patients admitted from July 2009 to July 2012 to the oncology ward of Instituto do Cancer do Estado de São Paulo as a result of symptomatic hypercalcemia were included in this retrospective analysis. Eligible patients fulfilled the following criteria: biopsy-proven solid tumors and serum ionized calcium \> 5.5 mg/dL (normal range, 4.6 to 5.3 mg/dL) or total Ca \> 10.5 mg/dL (normal range, 8.6 to 10.2 mg/dL) within 3 days of admission. All patients had symptoms related to hypercalcemia, such as altered mental status, dehydration, and constipation, or were referred by the treating physician for in-hospital management of hypercalcemia. Patients with concurrent causes of hospitalization also were included. Patients with chronic renal failure (glomerular filtration rate \< 30 mL/min/1.73 m^2^) before the episode of hypercalcemia and known primary hyperparathyroidism were excluded from this analysis. All data were extracted from medical records.

Overall survival (OS) was defined as the date of the first symptomatic hypercalcemic episode until death. Patients alive at the last date of contact were censored. Survival curves were estimated by the Kaplan-Meier method. To determine possible prognostic factors, log-rank test was used for univariable analysis. Variables with *P* \< .05 were selected for the multivariable Cox proportional hazards regression model. This study was approved by the local ethics committee.

RESULTS {#s4}
=======

Patient Characteristics {#s5}
-----------------------

Patient characteristics are listed in [Table 1](#T1){ref-type="table"}. Most were male (65%) with a median age of 57 years. Median time from diagnosis was 183 days. Squamous cell carcinoma was the most common histology (62%), and 68 patients (22%) had adenocarcinoma. Head and neck was the most frequent primary site (28%) followed by lung (15%), breast (10%), and esophagus (10%). The majority of patients (96%) had Eastern Cooperative Oncology Group PS \> 1, with most having a poor PS (45% with PS 3 and 34% with PS 4). The incidence rate for bone metastasis was 43%, and 168 patients (55%) had altered mental status. Nearly one half had not received previous chemotherapy (CT) at presentation. Sixty-nine patients (23%) were transferred to hospice during hospitalization.
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MRH Therapy {#s6}
-----------

Two hundred forty-three patients (79%) were treated with pamidronate and 11 (4%) with zoledronic acid. Most (97%) were treated with intravenous fluid therapy, 238 (78%) with furosemide, 212 (69%) with calcitonin, and 172 (56%) with corticosteroids. Seventy-eight patients (25%) received only one line of CT, and 20 (7%) received two or more lines after the first hypercalcemic episode.

Prognostic and Survival Analysis {#s7}
--------------------------------

No difference in OS was seen between patients treated with BP or not (30 *v* 40 *v* 47 days for no BP *v* pamidronate *v* zoledronic acid, respectively; *P* = .73). Moreover, other supportive therapy, such as the use of corticosteroids, did not influence survival. Time from diagnosis also did not have an influence on survival (103 *v* 95 days, below and above the median time from diagnosis, respectively; *P* = .34).

Median OS ([Fig 1](#F1){ref-type="fig"}) was 40 days (95% CI, 33 to 47 days). In the univariable analysis, PS \> 1, altered mental status, C-reactive protein \> 30 mg/L, albumin \< 2.5 g/dL, and body mass index \< 18 kg/m^2^ were associated with a worse prognosis ([Table 2](#T2){ref-type="table"}). Longer OS was observed among patients who were treatment naive, treated with subsequent CT (144 *v* 25 days; *P* \< .001), or had breast primary tumors ([Table 2](#T2){ref-type="table"}). In the multivariable analysis, only subsequent CT remained a significant favorable prognostic factor for OS (hazard ratio, 0.24; 95% CI, 0.14 to 0.40; *P* \< .001; [Fig 2](#F2){ref-type="fig"}; [Table 3](#T3){ref-type="table"}).

![Median overall survival after hypercalcemia. Patients admitted with symptomatic hypercalcemia experienced a short overall survival of 40 days.](JGO.2016.006890f1){#F1}
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![Chemotherapy (CT) survival impact in patients with symptomatic hypercalcemia. Patients who received additional CT had a significantly increased survival compared with patients who did not receive additional CT (144 *v* 25 days; *P* \< .001).](JGO.2016.006890f2){#F2}
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Prognostic Factors: Multivariable Analysis
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DISCUSSION {#s8}
==========

In this single-center retrospective study, a median OS of 40 days was observed in patients with MRH treated with BPs, which is a similar result to that observed in other series published in the past 20 years^[@B7]-[@B13]^ from various geographic regions. Studies of patients with breast cancer^[@B8],[@B14]^ showed a slightly better survival, which we also observed in the current series, that might be related to a greater exposure to systemic treatment and CT and/or hormonal sensitivity. In this large series of patients with symptomatic MRH, the most frequent primary site was head and neck in consonance with the European series of Penel and colleagues.^[@B11],[@B12]^ However, in another series by Soyfoo et al,^[@B15]^ the breast was the most frequent site (29%) and showed head and neck as the fifth most common site (8%). Such differences could be attributed to regional characteristics and distinct inclusion criteria. To our knowledge, the current series is the largest to evaluate prognostic factors and survival in MRH. Penel et al^[@B12]^ validated a prognostic score and showed that liver metastasis, squamous cell carcinoma, hypoalbuminemia, and total serum calcium levels \> 11.3 mg/dL are related to a poor prognosis and that patients with at least one prognostic factor have a median OS of 49 days. In the current study, multivariable analysis showed that posthypercalcemia CT was related to survival gain: 144 days for patients who received one or more lines of CT versus 25 days for patients with no further CT. These findings are similar to those reported by Ralston et al^[@B2]^ where the median OS was 135 days for patients who received CT after a hypercalcemic episode and 28 days for those with no further CT. Ling et al^[@B7]^ also found a significant difference of 86 days for those with further cancer treatment and 35 days for those with no further treatment.

The limitations of the current study are related to its retrospective design. We excluded patients with known primary hyperparathyroidism but did not routinely measure parathyroid hormone levels in patients with hypercalcemia. Until recently, the real proportion of patients with hypercalcemia who had cancer of a benign nature was not clear. In a large series, Soyfoo et al^[@B15]^ evaluated the etiology of hypercalcemia in patients with cancer and found that 199 (31%) of 642 patients had a non--cancer-related hypercalcemia cause. Among these patients, 115 had active disease and 84 were in complete remission. By far, primary hyperparathyroidism was the leading cause (79%). In the current series, parathyroid hormone assessment was performed at the discretion of the treating physician, which is an inherent limitation of the restrospective nature of this report. Even so, four (10%) of 40 patients in whom such an issue was assessed had high levels of parathyroid hormone and were excluded from the final analysis. Such a difference can be explained by the fact that all the patients had active disease. Soyfoo et al also evaluated the etiology for MRH; bone metastases was the cause of 53% of the events, 35.3% were humoral in origin, and 11.7% were a result of both conditions.^[@B15]^

To improve these poor outcomes, some investigators have studied anti-RANKL (receptor activator of nuclear factor-κB ligand) therapies, such as denosumab and antiparathyroid hormone--related protein antibodies.^[@B16]^ In a recent single-arm, phase II study, Hu et al^[@B17]^ showed that denosumab is a promising treatment of MRH refractory to BPs, with a response observed in 21 of 33 patients and a median duration of 104 days.

Hypercalcemia seemed to be a marker of advanced and uncontrolled disease occurring mainly when more parathyroid hormone-related peptide or when extensive bone metastasis are present. Although BPs have led to faster calcium normalization, studies have failed to demonstrate survival gain ([Table 4](#T4){ref-type="table"}). Supportive therapy is essential for symptom control, which leads to improved quality of life^[@B18]^ and high hospital discharge rates.^[@B2]^ Given that most patients with MRH have a short survival time, a decrease of in-hospital stay is of particular interest for those in the final stages of life. Patients who receive home-based palliative care have significantly less symptom severity and distress, lower depression scores, and better physical health and quality of life than those who receive inpatient care.^[@B23]^
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In this series, patients admitted to the hospital as a result of MRH had a median time from diagnosis of 6 months. The administration of CT after the first episode of MRH was related to a better survival, regardless of previous systemic treatment. This suggests that MRH control could affect the disease course by allowing patients to receive cancer treatment and that the adequate selection of patients who should undergo CT could alter the course of this syndrome.

In conclusion, despite advances in oncologic treatment and supportive care, patients with symptomatic MRH still have a dismal prognosis, with little to no survival gain over the past decades. The role of new drugs, such as targeted therapies and denosumab, needs to be further elucidated in this context.

Presented at the European Cancer Congress 2013, Amsterdam, the Netherlands, September 27-October 1, 2013.
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